U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416656) titled 'Validation of Hemoglobin A1c in Patients With Inflammatory Arthritis Treated With Sulfasalazine' on Feb. 10.
Brief Summary: The purpose of this study is to examine whether the blood test Hemoglobin A1c (HbA1c) gives an accurate picture of blood glucose levels in patients with inflammatory arthritis who are treated with sulfasalazine. HbA1c is widely used to diagnose and monitor diabetes, but sulfasalazine can shorten red blood cell lifespan and thereby lower HbA1c values independently of actual glucose levels.
This may lead to underdiagnosis of diabetes in patients who develop diabetes during sulfasalazine treatment, and to undertr...